Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Hires at Illumina, Applied BioCode, and Cepheid

Premium

Illumina this week named Charles Dadswell as senior vice president and general counsel.

Dadswell takes over for Christian Cabou, who has retired. He will have worldwide responsibility for all legal and IP matters, and will serve as secretary to Illumina's board of directors.

Dadswell joins Illumina from BioMérieux, where he was most recently vice president, general counsel for North and Latin America and corporate director of global intellectual property.

Prior to BioMérieux, he was general counsel of BioDelivery Sciences International; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome, and GlaxoSmithKline.


Applied BioCode said this week that Michael Aye is the company's new vice president of molecular products.

Aye has more than eight years of research and development experience at companies such as Focus Diagnostics (a division of Quest Diagnostics) and Beckman Coulter. Prior to his industrial experience Aye spent 10 years in academia focused on research in molecular genetics and microbiology.


Cepheid disclosed during its first-quarter earnings call last week that Warren Kocmond will join the company on May 6 as executive vice president of global operations.

Kocmond is currently vice president of global operations for Lam Research, and has previously served as executive vice president of memory products at Verigy; CEO of Electroglas; and senior vice president of global operations at Affymetrix.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.